期刊文献+

gyrA和parC基因与粪肠球菌对氟喹诺酮类抗菌药物耐药的关系 被引量:5

Relationship between gyrA and parC genes and Enterococcus faecalis to fluoroquinolone resistance
下载PDF
导出
摘要 目的探讨粪肠球菌DNA解旋酶和拓扑异构酶Ⅳ基因与氟喹诺酮类抗菌药物的耐药的关系,为临床治疗和新药的开发提出实验依据。方法用琼脂稀释法检测112株粪肠球菌对4种氟喹诺酮类抗菌药物的体外敏感试验,并选择对氟喹诺酮类抗菌药物耐药的菌株对其gyrA和parC的喹诺酮耐药决定区域基因进行PCR扩增,然后随机选择5株PCR产物纯化后直接测序经基因同源性分析(BLAST)分析其氨基酸序列。结果 4种氟喹诺酮类抗菌药物对粪肠球菌的抑菌效果依次为:加替沙星>左氧氟沙星>诺氟沙星、环丙沙星;5株菌的gyrA基因有4株第83位氨基酸发生了改变,parC基因均发生了突变。结论粪肠球菌对氟喹诺酮类药物的耐药情况严重,gyrA基因和parC基因的氨基酸突变是引起粪肠球菌对氟喹诺酮类抗菌药物产生耐药的重要原因。 Objective To study DNA gyrase and topoisomerase Ⅳ gene mutation to fluoroquinolone resistance and provide experimental evidence in treatment for clinical and developing new drugs.Methods Detected by agar dilution method against 112 strains of Enterococcus faecalis 4 fluoroquinolone antibiotics in vitro susceptibility testing,and PCR amplified QRDR of gyrA and parC that quinolone resistant strains,Then randomly selected 5 direct sequencing of PCR products were purified and compared by BLAST analysis of its amino acid sequence.Results 4 fluoroquinolone antibiotics against E.faecalis on the antibacterial activity as follows: GATLVXNOR and CIP.GyrA gene had changed with Ser83→Ile(AGT→ATT)and Ser83→Tyr(AGT→TAT);parC genes occurred mutation with Ser80→Ile(AGC→ATC),Ser48→Leu(TCA→TTA),Met89→Leu(ATG→CTA),Lys94→Ile(AAG→ATA).Conclusion Enterococcus faecalis resistant to fluoroquinolones in serious condition.The mutation of gyrA and parC gene is an important reason of E.faecalis resistant to fluoroquinolone antibiotics.
出处 《安徽医科大学学报》 CAS 北大核心 2011年第4期349-351,共3页 Acta Universitatis Medicinalis Anhui
基金 安徽省自然科学研究基金(编号:09020103002)
关键词 抗药性 细菌 微生物敏感性试验 粪肠球菌 drug resistance bacterial microbial sensitivity tests Enterococcus faecalis
  • 相关文献

参考文献7

二级参考文献50

  • 1罗燕萍,白立彦,李俊玲,许淑秀.211株肠球菌属细菌对18种抗生素的耐药性特征[J].中华医院感染学杂志,2004,14(1):80-82. 被引量:68
  • 2朱德妹,汪复,张婴元.2003年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(1):4-12. 被引量:147
  • 3林彦,赵莉萍,俞森洋.肺部肠球菌医院感染的特点及耐药性分析[J].中华医院感染学杂志,2005,15(3):333-335. 被引量:7
  • 4Oyamada Y,Ito H,Inoue M,et al.Topoisomerase mu-tations and efflux are associated with fluoroquinoione resistance in Enterococcus faecalis[J].Journal of Medical Microbiology,2006,55(10):1395-1401.
  • 5Leavis HL,Willems RJ,Top J,et al.High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CCl7 of Enterococcus faecium[J].J Clin J Biol,2006,44(3):1059-1064.
  • 6Clinical and Laboratory Standards Institute.Performance standards for antimierobial susceptibility testing[S].17th informantional supplement M100S17,2007.
  • 7Grohs P,Houssaye S,Aubert A,et al.In vitro activities of garenoxacin(BMSr284756)against Streptococcus pneumoniae,viridans group streptococci,and Enterococcus faecalis compared to those of six other quinolones[J].Antimicrob Agents Chemother,2003,47(11):3542-3547.
  • 8Chen FJ,Lo HJ.Molecular mechanisms of fluoroquinoione resistance[J].J Microbiol Immunol Infect,2003,36(1):1-9.
  • 9Onodera Y,Okuda J,Tanaka M,et al.Inhibitory Acti-vities of Quinolones against DNA GyrAse and Topoisomerase Ⅳ of Enterococcus faecalis[J].Antimicrob Agents Chemother,2002,46(6):1800-1804.
  • 10el Amin NA,Jalal S,Wretlind B.Alterations in GyrA and ParC associated with fluoroquinoione resistance in Enterococcus faecium[J].Antimicrob Agents Chemother,1999,43(4):947-950.

共引文献26

同被引文献71

  • 1Kobayashi C C, Sadoyama G, Vieira J D, et al. Associated antimicrobial resistance in Enterococcus spp. clinical isolates[J]. Rev Soc Bras Med Trop, 2011, 44 : 344-348.
  • 2Creti R, Imperi M, Bertuccini L, et al. Survey for virulence determinants among Enterococcus faecalis isolated from different sources [J]. JMed Microbiol, 2004, 53(Pt1): 13-20.
  • 3Sulochana S, Rahaman F, Paramasivan C N. In vitro activity of fluoro-Quinolones against Mycobacterium tuberculosis [J]. J Chemother, 2005, 17(2): 169-173.
  • 4Schaberg D R, Dillon W I, Terpenning M S, et al. Increasing resistance of enterococci to ciprofloxacin [J]. Antimierob Agents Chemother, 1992, 36(11): 2533-2535.
  • 5Tankovic J, Mahjoubi F, Courvalin P, et al. Development of fluoroquinolone resistance in Enterococcusfaecalis and role of mutations in the DNA gyrase gyrA gene [J]. Antimicrob Agents Chemother, 1996, 40(11): 2558-2561.
  • 6Grohs P, Houssaye S, Aubert A, et al. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faeealis compared to those of six other quinolones [J]. Antimierob Agents Chemother, 2003, 47(11): 3542-3547.
  • 7Hooper D C. Emerging mechanism of fluoroquinolone resistance[J]. Emerg lnfect Dis, 2001, 7(2): 337-341.
  • 8Levine C, Hiasa H, Marians K. DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities [J]. Biochim BiophysActa, 1998, 1400(1-3): 29-43.
  • 9Onodera Y, Okuda J, Tanaka M, et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis[J]. Antimicrob Agents Chemother, 2002, 46(6): 1800-1804.
  • 10Wang H, Dzink-Fox J L, Chen M, et al. Genetic characterization of highly fluoro-quinolone-resistant clinical Escherichia coli strains from China: role of aerR mutations[J]. Antimicrob Agents Chemother, 2001, 45(5): 1515-1521.

引证文献5

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部